Soleno Therapeutics (SLNO) Short-Term Debt repayments (2015)
Soleno Therapeutics (SLNO) reported Short-Term Debt repayments of -$471.0 for Q4 2015, down 100.46% on a QoQ basis from $102000.0 in Q1 2015.
Soleno Therapeutics (SLNO) has 1 years of Short-Term Debt repayments data on file, last reported at -$471.0 in Q4 2015.
- Quarterly Short-Term Debt repayments changed N/A year-over-year to -$471.0 in Q4 2015, while the trailing twelve-month figure through Sep 2016 was -$471.0 (changed N/A YoY) and the FY2015 annual result came in at $101529.0, changed N/A from the prior year.
- Short-Term Debt repayments slipped to -$471.0 in Q4 2015 per SLNO's latest filing, from $102000.0 in the prior quarter.
- Across five years, Short-Term Debt repayments topped out at $102000.0 in Q1 2015 and bottomed at -$471.0 in Q4 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 102,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | -471.00 |
| Dec 31, 2015 | -471.00 |
| Mar 31, 2015 | 102,000.00 |
| Mar 31, 2015 | 102,000.00 |